Return on public health investment: CDC's expanded HIV testing initiative

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 281-286

  Hutchinson, Angela B ^a   Farnham, Paul G ^a   Duffy, Nadezhda ^a   Wolitski, Richard J ^a   Sansom, Stephanie L ^a   Dooley, Samuel W ^a   Cleveland, Janet C ^a   Mermin, Jonathan H ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cost; Economics; HIV; Resource allocation; Return on investment; Testing

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; SEXUAL TRANSMISSION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COST-BENEFIT ANALYSIS; HIV; HIV INFECTIONS; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; PUBLIC HEALTH; UNITED STATES; YOUNG ADULT;

EID: 84859785695     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823e5bee     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention (CDC). Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001;50: 1-58.
2. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55: 1-17.
3. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146: 87-95.
4. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2009;375: 2092-2098.
5. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20: 1447-1450. (Pubitemid 43948252)
6. Gorbach PM, Weiss RE, Jeffries R, et al. Behaviors of recently HIVinfected men who have sex with men in the year post-diagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr. 2011;56: 176-182.
7. CDC. Late HIV Testing-34 States, 1996-2005. MMWR Morb Mortal Wkly Rep. 2009;58: 661-665.
8. CDC. Results of the Expanded HIV Testing Initiative-25 Jurisdictions, United States, 2007-2010. MMWR Morb Mortal Wkly Rep. 2011;60: 806-810.
9. CDC. Vital signs: HIV testing and diagnosis among adults-United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2010;59: 1550-1555.
10. Campsmith M, Rhodes PH, Hall HI, et al. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53: 619-624.
11. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153: 778-789.
12. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005;352: 586-595. (Pubitemid 40204671)
13. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352: 570-585. (Pubitemid 40204670)
14. Luce BR, Mauskopf J, Sloan FA, et al. The return on investment in health care: from 1980 to 2000. Value Health. 2006;9: 146-156.
15. Grosse SD, Sotnikov SV, Leatherman S, et al. The business case for preconception care: methods and issues. Matern Child Health J. 2006; 10(5 suppl): S93-S99.
16. Hutchinson AB, Patel P, Sansom SL, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after thirdgeneration HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7: e1000342.
17. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44: 990-997. (Pubitemid 44674030)
18. Marks G, Crepaz N, Senterfitt JW, et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39: 446-453. (Pubitemid 41003791)
19. Lasry A, Sansom SL, Hicks KA, et al. A model for allocating CDC's HIV prevention resources in the United States. Health Care Manag Sci. 2011;14: 115-124.
20. Prabhu VS, Hutchinson AB, Farnham PG, et al. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS. 2009;23: 1792-1794.
21. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the costeffectiveness of methadone maintenance. Am J Public Health. 2000;90: 1100-1111. (Pubitemid 30445365)
22. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300: 520-529.
23. White DE, Scribner AN, Schulden JD. Results of a rapid HIV screening and diagnostic testing program in an urban emergency. Ann Emerg Med. 2009;54: 56-64.
24. Golden MR, Stekler J, Wood RW. Trends in the frequency of HIV testing and CD4 count at diagnosis among persons tested through a public health program in Seattle, WA USA, 1995-2008. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada.
25. Lyons MS, Lindsell CJ, Hawkins DA, et al. Contributions to early HIV diagnosis among patients linked to care vary by testing venue. BMC Public Health. 2008;8: 220.
26. Panel on Antiretroviral guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2011: 1-174. Available at: http: //www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 2011.
27. Trogdon J, Finkelstein EA, Reyes M, et al. A return-on-investment simulation model of workplace obesity interventions. J Occup Environ Med. 2009;51: 751-758.
28. Prabhu VS, Farnham PG, Hutchinson AB, et al. Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One. 2011;6: e19936.
29. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol. 2008;46: 1588-1595. (Pubitemid 351657199)
30. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med. 2010;170: 66-74.
31. Martin EG, Paltiel AD, Walensky RP, et al. Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. Value Health. 2010;13: 893-902.